AZTA
Azenta·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
Significant Net Income Decline
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AZTA
Azenta, Inc.
A global provider of life sciences and advanced specialty chemicals
Semiconductor Products and Equipment
--
02/03/1995
NASDAQ Stock Exchange
3,000
09-30
Common stock
200 Summit Drive 6th Floor, Burlington, Massachusetts 01803
--
Azenta, Inc., is a Delaware corporation established in 1978. The company is a leading global provider of biological and chemical compound sample exploration and management solutions for the life science industry. The company entered the life sciences market in 2011, leveraging the in-house precision automation and cryogenic capabilities they applied in the semiconductor manufacturing market at the time. Since then, the company has expanded its life science offerings through internal investments and a series of acquisitions. The company now supports clients from research and clinical development to commercialization with sample management, automated storage and genomic services expertise to help clients bring influential therapies to market faster. The company understands the importance of sample integrity and supports customers with a broad portfolio of products and services at every stage of the sample life cycle, including procurement and procurement, automated storage systems, genomic services and bulk sample consumables, informatics and data software, and sample repository solutions.
Earnings Call
Q2/2025
Estimate EPS0.07
Actual EPS0.05
Estimate Revenue140.76M
Actual Revenue143.00M
Azenta's Q2 2025: Navigating Key Contradictions on NIH Headwinds, EBITDA Margins, and Market Growth
May 07,2025 01:45
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS0.14
Actual EPS0.19
Estimate Revenue149.81M
Actual Revenue144.00M
Azenta's Q3 2025: Contradictions Emerge on NIH Funding, Strategic Pivots, Gene Synthesis, Leadership Changes, Multiomics Guidance, and EBITDA Margin Expansion
Nov 21,2025 10:17
Earnings Decrypt
Earnings Decrypt
Q4/2025
Estimate EPS0.2
Actual EPS0.21
Estimate Revenue156.36M
Actual Revenue159.00M
Azenta's Q4 2025: Contradictions Emerge on Macroeconomic Impact, NGS Growth, and Government Shutdowns
Nov 21,2025 01:05
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
AZTA has released its 2025 Q4 earnings. EPS was reported at 0.21, versus the expected 0.2, beating expectations. The chart below visualizes how AZTA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
AZTA has released its 2025 Q4 earnings report, with revenue of 159.19M, reflecting a YoY change of 5.70%, and net profit of 47.14M, showing a YoY change of 810.00%. The Sankey diagram below clearly presents AZTA's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
